New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:40 EDTPBMD, CYTX, HART, CAPR, ATHX, CELG, NBS, BLUE, FATEAlliance for Regenerative Medicine to hold a conference
2nd Annual Regen Med Investor Day is being held in New York on March 26 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
News For BLUE;FATE;PBMD;CYTX;HART;CAPR;ATHX;CELG;NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
October 17, 2014
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:31 EDTHARTHarvard Apparatus says patient in transplant study passes away
Subscribe for More Information
October 16, 2014
15:10 EDTCELGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
October 15, 2014
14:47 EDTCYTXSabby reports 9.99% passive stake in Cytori Therapeutics
Subscribe for More Information
October 14, 2014
08:59 EDTPBMDPrima BioMed announces Immutep IMP321 receives Australian notice of allowance
Prima BioMed announced that Immutep S.A. has received a Notice of Allowance from the Australian Patent Office for Patent Application AU 2008306576 "Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response". As announced on 2 October Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity to fund the acquisition. The AGM will be held on November 14. The patent provides protection for the use of soluble recombinant LAG-3 Ig, or IMP321, or derivatives thereof, notably in combinations, in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in the blood. This invention is currently in clinical trials for the treatment of cancer and the broad claims allowed will provide options for numerous clinical applications. By increasing the number of monocytes or antigen presenting cells in the blood, IMP321 can stimulate increased cytotoxic T cell responses against cancer antigens. Immutep has conducted clinical trials using IMP321 as a monotherapy, an adjuvant and in combination with chemotherapy.
08:17 EDTCAPRCapricor Therapeutics to acquire certain patent rights from Medtronic
Capricor Therapeutics (CAPR) announced that it has entered into an agreement to acquire patent rights from Medtronic (MDT) relating to the formulation and pump delivery of natriuretic peptides. Capricor recently announced that it plans to develop a clinical program using Cenderitide, a natriuretic peptide, for the treatment of post-acute heart failure.
07:04 EDTBLUEbluebird bio says first patient with sicle cell disease undergoes infusion
Subscribe for More Information
06:05 EDTNBSBioLife Solutions biopreservation products used at Progenitor Cell Therapy
BioLife Solutions (BLFS) provided an update on use of the company's HypoThermosol storage/shipping media and CryoStor cryopreservation freeze media by Progenitor Cell Therapy, or PCT, a wholly owned subsidiary of NeoStem (NBS) a leader in the emerging cellular therapy field.
October 10, 2014
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
October 8, 2014
08:04 EDTCYTXCytori Therapeutics raises $13.5M in a registered direct offering
Subscribe for More Information
07:11 EDTCELGEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
October 7, 2014
07:31 EDTCELGCelgene to present long-term efficacy and safety data on oral Otezla
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that the latest research findings on OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in plaque psoriasis and psoriatic arthritis will be presented at the 23rd European Academy of Dermatology and Venereology Congress in Amsterdam, October 8 – 12. In total, 11 abstracts will be presented at the meeting. OTEZLA data to be presented include long-term results from Celgene’s pivotal trial, ESTEEM 2 and pooled analyses of safety and tolerability results from the ESTEEM 1 and 2 studies in patients with moderate to severe plaque psoriasis. Additional analyses will evaluate the effect of OTEZLA on pruritus, difficult-to-treat areas such as nail and scalp, and palmoplantar psoriasis, work productivity and improvements in health-related quality of life. An analysis of long-term results from the PALACE clinical trial program evaluating OTEZLA in patients with active psoriatic arthritis will also be presented at the meeting. The analysis assesses the effect of OTEZLA treatment through 52 weeks on the signs and symptoms of psoriatic arthritis, including enthesitis and dactylitis in patients with pre-existing enthesitis or dactylitis.
07:24 EDTBLUE, NBS, CELG, ATHXAlliance for Regenerative Medicine
Subscribe for More Information
07:16 EDTBLUE, NBSBiotech Industry Organization to hold a forum
Subscribe for More Information
October 6, 2014
07:34 EDTCELGAlliqua expands exclusive licensing agreement with Celgene
Alliqua Biomedical (ALQA) announced that the company has amended its exclusive licensing agreement with Celgene Cellular Therapeutics, or CCT, a subsidiary of Celgene (CELG). Under the terms of the amended agreement, Alliqua has received the right to market the advanced wound care product, Biovance, for podiatric and orthopedic applications. Biovance is a, decellularized, and dehydrated, human amniotic membrane allograft, which was commercially launched by Alliqua on April 23. The product is currently indicated for the management of non-infected partial- and full-thickness wounds, including chronic and acute wounds such as diabetic ulcers, pressure ulcers, venous ulcers, chronic vascular ulcers, tunnel/undermined wounds, surgical wounds, trauma wounds, and draining wounds, The field of use for Biovance has been expanded to include podiatric and orthopedic applications including sports medicine-related conditions pertaining to use during the repair of tendon, nerve and bone in the foot and ankle, as well as other surgical procedures in these specialty areas.
07:32 EDTNBSNeoStem announces USAN approval of generic name 'Eltrapuldencel-T'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use